What is Rhythm Pharmaceuticals, Inc.'s gross unrealized gains?

Rhythm Pharmaceuticals, Inc. (RYTM) reported gross unrealized gains of $168K in Q1 2026.

Rhythm Pharmaceuticals, Inc. RYTM Gross Unrealized Gains

Gross Unrealized Gains at other companies

Mirum Pharmaceuticals, Inc.MIRM

——

BridgeBio PharmaBBIO

——

ExelixisEXEL

——

Ionis PharmaceuticalsIONS

——

MedtronicMDT

——

Merck & Co.MRK

——

Other financials

Income statement

See full

Revenue$60.1M+83.8%

Gross profit$53.0M+82.3%

Operating income-$52.4M-11.4%

Net income-$55.6M-12.4%

EPS (diluted)-$0.83-2.5%

Balance sheet

See full

Cash & equivalents$62.1M-41.4%

Total debt$112.3M-1.1%

Total equity$122.9M+549%

Total assets$442.3M+14.4%

Cash flow

See full

Operating cash flow-$44.2M-9.5%

CapEx$238.3K—

Free cash flow-$29.2M-2.4%

Valuation

See full

Market cap$6.64B+77.3%

Enterprise value$6.69B+78.4%

P/S30.6×+3.2×

Profitability

See full

Gross margin89.4%-0.2pp

Operating margin-90.9%-19.8pp

Net margin-93.3%-18.2pp

FCF margin-61.5%-14.1pp

Returns & leverage

See full

Return on equity-285.8%-68.9pp

Debt / equity0.9×-5.1×

Current ratio4.2×+0.9×

Where this comes from

Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.

The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rhythm Pharmaceuticals, Inc.'s gross unrealized gains.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Rhythm Pharmaceuticals, Inc.'s gross unrealized gains?: Rhythm Pharmaceuticals, Inc. (RYTM) reported gross unrealized gains of $168K in Q1 2026.